sofosbuvir - Profile

What are the generic sources for sofosbuvir and what is the scope of patent protection?

Sofosbuvir is the generic ingredient in four branded drugs marketed by Gilead Sciences Inc and Teva Pharms Usa Inc, and is included in six NDAs. There are twenty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sofosbuvir has three hundred and sixty-nine patent family members in fifty countries.

Summary for sofosbuvir

International Patents:	369
US Patents:	22
Tradenames:	4
Applicants:	2
NDAs:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for sofosbuvir

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for sofosbuvir

Constraining patent/regulatory exclusivity:

FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN

Dosage:

PELLETS;ORAL

Constraining patent/regulatory exclusivity:

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for SOFOSBUVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SOVALDI	Tablets	sofosbuvir	400 mg	204671	2	2017-12-06

US Patents and Regulatory Information for sofosbuvir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	SOVALDI	sofosbuvir	PELLETS;ORAL	212480-001	Aug 28, 2019		RX	Yes	No					Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	PELLETS;ORAL	212480-001	Aug 28, 2019		RX	Yes	No					Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	PELLETS;ORAL	212480-001	Aug 28, 2019		RX	Yes	No					Y
Gilead Sciences Inc	SOVALDI	sofosbuvir	PELLETS;ORAL	212480-001	Aug 28, 2019		RX	Yes	No					Y

EU/EMA Drug Approvals for sofosbuvir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Sovaldi	sofosbuvir	EMEA/H/C/002798Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.	Authorised	no	no	no	2014-01-16

International Patents for sofosbuvir

Country	Patent Number	Title	Estimated Expiration
Argentina	066898	DERIVADOS DE FOSFORAMIDATO DE NUCLEOSIDOS. PROCESOS DE OBTENCION Y COMPOSICIONES FARMACEUTICAS.
Argentina	110411	DERIVADOS DE FOSFORAMIDATO DE NUCLEÓSIDO
Australia	2008232827	Nucleoside phosphoramidate prodrugs
Brazil	PI0809654	Composto, seu estereoisômero, sal, hidrato, solvato, ou forma cristalina do mesmo e processo para preparar o mesmo e uso do mesmo, composição para tratamento e/ou profilaxia de quaisquer agentes virais, uso de composto, método de tratar indivíduo

Supplementary Protection Certificates for sofosbuvir

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	826	Finland
2203462	2014/065	Ireland		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-EU/1/13/894/002 20140116
2203462	PA2014040	Lithuania		PRODUCT NAME: SOFOSBUVIRUM; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116
2203462	C300704	Netherlands		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117

Sofosbuvir: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

Sofosbuvir, marketed primarily under the brand name Sovaldi by Gilead Sciences, is a nucleotide analog inhibitor used in treating hepatitis C virus (HCV) infections. Introduced in 2013, it revolutionized HCV therapy, boasting cure rates exceeding 90%. This article analyzes the current investment landscape, market environment, and projected financial performance of sofosbuvir, considering patent status, competitive dynamics, pricing strategies, and geographic expansion. The analysis provides insights for investors, pharma stakeholders, and policy makers assessing future value and risks associated with sofosbuvir.

---

What Is the Current Status of Sofosbuvir’s Market?

Aspect	Details	Implication
Market Launch	2013	Early-mover advantage, rapid market share growth
Patent Expiry	Expected around 2029-2030 (varies by country)	Increased generic competition, potential revenue decline
Approved Indications	Chronic hepatitis C (all genotypes), in combination with other agents	Broad global use potential
Global Reach	Available in over 100 countries	Expanding market size, especially in emerging markets
Major Competitors	Harvoni (Gilead), Epclusa (Gilead), quad therapies (AbbVie, Merck)	High competition, driving price reductions

---

Market Dynamics Influencing Sofosbuvir’s Investment Trajectory

Patent Landscape and Intellectual Property

Key Timeline	Event	Impact
2013	Patent filing and launch	Monopoly pricing, high margins
2015-2017	Patent challenges in India, Egypt, and Thailand	Threats to exclusivity, generic entrants emerging
2018-2022	Patent defenses maintained in core markets	Extended exclusivity, sustained revenues
2023+	Anticipated patent cliffs in select jurisdictions	Revenue erosion, increased generic competition

Source: Gilead’s patent filings and legal battles (see [1], [2])

Pricing Strategies and Market Penetration

Year	Price per Treatment Course (USD)	Adjusted Prices (Emerging Markets)	Notes
2013	~$84,000	Discounted to ~$10,000–$15,000	Price reduction driven by negotiations and generics
2017	~$50,000–$70,000	Further discounts, tiered pricing	Adoption in developing countries expands
2022	~$24,000–$30,000	Prices vary; some markets see <$10,000	Cost-containment and competition accelerate

Implication: The decreasing price trends influence future revenue projections, especially post-patent expiry.

Market Size and Growth Opportunities

Region	HCV Population (millions)	Market Penetration	Growth Drivers
North America	~2.5	High	Screening programs, reimbursed treatments
Europe	~3.0	Moderate	Increasing awareness, national strategies
Asia-Pacific	~20	Low to moderate	Growing healthcare infrastructure, generic availability
Latin America	~5	Increasing	Price competition and government programs

Note: The global HCV population approximates 71 million, with substantial undiagnosed burdens in lower-income regions.

---

Financial Trajectory Projections

Revenue Forecasts

Year	Estimated Global Revenue (USD)	Assumptions	Notes
2023	~$8 billion	Post-pandemic recovery, continued demand	Steady decline in high-income markets, sustained in emerging markets
2025	~$5–6 billion	Patent cliff approaches in some territories	Revenue decline accelerates, shift to generics
2030	<$2 billion	Most markets face generic competition	Potentially negligible in mature markets

Sources: Gilead Sciences annual reports (2022), market research (IQVIA, 2022)

Profitability Outlook

Factor	Current Status	Projected Impact
Gross Margin	~80% in branded markets	Compression post-patent expiry
Operational Costs	R&D, marketing, legal expenses	Stable but relatively high
Net Margin	~50–60%	Likely to decline in patent expiry periods

---

Comparison with Competing Therapies

Therapy	Composition	Market Share (2022)	Price Range	Key Differentiator
Harvoni	Ledipasvir/sofosbuvir	30–40%	~$74,000	Fixed-dose, high efficacy
Epclusa	Sofosbuvir/velpatasvir	25–30%	~$75,000	Pan-genotypic use
Vosevi	Sofosbuvir/velpatasvir/voxilaprevir	10–15%	~$90,000	Salvage therapy

Implication: The market is consolidating around high-efficacy combinations, potentially diluting sofosbuvir’s standalone value.

---

Regulatory and Policy Factors

Policy Area	Impact on Investment	Notes
Pricing Regulations	Downward pressure on prices	Many countries impose price caps
Patents & Exclusivity	Affect market access	Patent cliffs threaten revenue streams
Reimbursement Policies	Influence patient access	Treated populations grow with favorable policies
Generic & Biosimilar Entry	Accelerates revenue decline	Highly relevant post-patent expiration

---

Future Outlook and Strategic Considerations

Scenario	Description	Investment Implication
Optimistic	Continued adoption, new indications, and combination therapies sustain revenues	High long-term value if patent protections last beyond 2029
Moderate	Patent expirations lead to increased generics, but niche markets persist	Revenue declines but still attractive in specific regions
Pessimistic	Rapid patent cliff, aggressive generics, and price erosion erode profits significantly	Significant downside risk

Key Strategy: Early diversification into combination therapies, especially where patent expirations loom, can buffer potential declines.

---

Deep Dive: Investment Risks and Opportunities

Risks:

• Patent expiration leading to generic competition
• Price erosion due to market saturation
• New, more effective patented therapies emerging
• Regulatory barriers in certain jurisdictions

Opportunities:

• Expansion into underserved markets
• Development of combination regimens extending patent life
• Licensing and strategic alliances
• Diversification into HCV diagnostics and vaccines

---

Concluding Analysis

Sofosbuvir’s financial trajectory is marked by high initial revenues driven by monopolistic pricing, subsequent declines due to patent expirations and market saturation. Despite this, it remains a cornerstone of hepatitis C treatment, with significant opportunities in emerging markets and combination therapies extending its lifecycle. Investors should weigh patent risks, generics entry, and global healthcare policies when assessing long-term value.

---

Key Takeaways

• Patent protection remains critical; impending expiries (~2029–2030) pose revenue risks.
• Pricing strategies have successfully expanded access, but declining prices compress margins.
• Market competition from newer regimens limits potential growth in mature markets.
• Emerging markets provide growth avenues, especially with affordable generics.
• Diversification into combination therapies and adjacent HCV markets can sustain revenue streams.

---

Frequently Asked Questions

1. When is sofosbuvir’s patent expected to expire, and what are the implications?
   Most patents in key regions like the US and EU are expected to expire around 2029–2030, opening markets for generic competition, thus reducing revenues unless mitigated by new formulations or combination therapies.

2. Are there opportunities for profitable investments post-patent expiry?
   Yes, particularly through licensing agreements, entry into emerging markets with generics, and developing new combination drugs that extend the patent life.

3. How does competition impact sofosbuvir’s price and market share?
   Competition from other direct-acting antivirals (DAAs) and generics results in significant price reductions and market share shifts toward newer, pan-genotypic formulations.

4. What regulatory challenges could affect sofosbuvir’s future?
   Stringent pricing controls, patent challenges, and delays in approvals for new formulations could impair long-term profitability.

5. What are the prospects for sofosbuvir in developing countries?
   Generally strong, due to favorable pricing, government adoption programs, and the availability of affordable generics, though regulatory hurdles may vary by country.

---

References

[1] Gilead Sciences. (2022). Annual Report.
[2] IQVIA. (2022). Global Oncology Market Report.
[3] Patent databases and legal case studies relevant to Gilead’s patent rulings.
[4] World Health Organization. (2022). Hepatitis C Fact Sheet.
[5] MarketResearch.com. (2022). Hepatitis C Treatment Market Outlook.

---

This analysis provides a comprehensive view of sofosbuvir’s current status, market drivers, financial outlook, and strategic risks, equipping stakeholders with data-driven insights essential for making informed decisions.